ResearchAndMarkets.com’s offering.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of Congenital Hyperinsulinism (CHI), Type-specific Diagnosed Prevalence based on Cause of Congenital Hyperinsulinism (CHI), Type-specific Diagnosed Prevalence based on Histological Presentation of Congenital Hyperinsulinism (CHI) and Mutation-specific Diagnosed Prevalence of Congenital Hyperinsulinism (CHI) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
Congenital Hyperinsulinism (CHI) Detailed Epidemiology Segmentation
The total diagnosed prevalent population of CHI in the seven major markets was found to be 20,008 in 2017.